RenovoRx, Inc.

Good afternoon. I will be your conference call operator today. Please note that today's call is being recorded and all participants other than management are in listen-only mode. There will be a Q&A session following the management's presentation. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead. Thank you.

Thank you, Operator. Good afternoon, everyone, and welcome to Renovo Rx's third quarter 2025 conference call. I'm joined today by members of our leadership team, Dr. Ramtan Agha, Chairman, Founder, and Chief Medical Officer, Sean Begay, Chief Executive Officer, Lisa Gentry, Chief Clinical Officer, and Ronald Kozak, VP, Controller, and Principal Accounting Officer. Before we begin, I'd like to remind everyone that statements made during today's call contain or may contain forward-looking statements. covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding Renovo's clinical and commercial plans, strategies, and estimates of performance, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our Form 10-Q for the third quarter of 2025 and our most recent Form 10-K, for a detailed discussion of the risks and uncertainties facing Renovo Rx. With that, I'd like to turn the call over to our chairman, founder, and chief medical officer, Dr. Ramtan Agha.

Thank you, Walter, and good afternoon, everyone. This quarter marks another important step forward in Renovo Rx's 14-year journey transforming a bold concept into a new therapeutic option that is now reaching patients across the country. Our Preparatory Transverterial Microperfusion Therapy Platform, or TAMP, is designed for targeted therapeutic drug delivery across the arterial wall near the tumor site to bait the target tumor. By localizing and targeting delivery of therapeutic agents via the peripheral vascular system, TAMP is designed to optimize drug concentration where it's needed. This targeted approach is designed to minimize systemic exposure and toxicities related to chemotherapy and address the longstanding challenge in cancer care of poor blood supply to tumor sites. We believe that TAMP represents a significant advancement in the way cancer treatment can be approached. For decades, pancreatic cancer treatment has revolved around three pillars, surgery, radiation, and chemotherapy. We're proud to be introducing TAMP as the fourth option for patients diagnosed with solid tumors. What began as an idea tested in controlled clinical trials is now translating into real-world impact. Several times a week, a patient somewhere in the US is being treated with our TAMP technology. and that is deeply meaningful to our team. The early signs of clinical adoptions are promising. We're seeing interest and adoption from academic medical centers, NCI-designated cancer centers, and large community hospitals. Importantly, physicians who have used TAMP enabled by reNOVA-CAB are treating additional patients, validating the utility and safety of our technology. We are also expanding engagement across disciplines, including interventional radiology, surgical oncology, medical oncology, and radiation oncology, reflecting the truly multidisciplinary nature of our platform. To support this effort across multiple specialty lines, we have launched our TAMP workshop series in an online peer-to-peer forum. We're also proud to be expanding our scientific advisory board with world-renowned physicians who believe in the potential of our technology. Our mission is to integrate our approach to therapeutic drug delivery into the standard of care and ultimately improve patient outcomes by offering a more targeted and tolerable treatment path. With that, I turn it over to our CEO, Sean Begay, to share some details on our commercial and clinical progress.